IDEXX Laboratories, Inc.
NASDAQ:IDXXMedical - Diagnostics & Research
+$12.33 today
- Market cap
- $55.03B
- Beta
- 1.54
- P/E (TTM)
- 40.8
- EPS (TTM)
- $13.67
Volume 0.37M
Average 0.58M
IDXX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
IDEXX Laboratories, Inc.NASDAQ: IDXX
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development grows in line with its trailing trend
Q3 FY2026 research & development of $68.82M rose 8.5% year over year, behind the +10.2% change in trailing-twelve-month research & development. Sequentially, it rose 5.2% from the prior quarter. Over 3 fiscal years it compounded at -0.5% a year.
Context
- Research & development amounted to 5.8% of revenue in FY2025, up 0.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +8.5% toward the trailing-twelve-month pace of +10.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 251.21M USD
- Year-over-year change
- +14.3%
- 4-year CAGR
- +11.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 251.21M | +14.3% |
| FY2024 | 2024-12-31 | 219.79M | +15.1% |
| FY2023 | 2023-12-31 | 190.95M | -25.1% |
| FY2022 | 2022-12-31 | 254.82M | +58.3% |
| FY2021 | 2021-12-31 | 161.01M | — |
Research & Development vs competitors
How IDXX compares with its peers on the latest reported figures
- IDXX's LTM Sep 2026 research & development of $266.87M is the 4th highest of the 5 companies compared; the peer median is $551.5M.
- Its year-over-year change of +10.2% is the 2nd highest of 5, against a peer median of +6.4%.
- Research & development amounts to 5.7% of revenue for IDXX, versus a peer median of 7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $28.35B | +65.7% | -2.6% | 42.7% | |
| LTM Jun 2026 | $722M | +5.9% | +9.0% | 7.6% | |
| LTM Sep 2026 | $381M | +7.0% | +4.7% | 7.4% | |
| LTM Sep 2026 | $266.87M | +10.2% | -0.5% | 5.7% | |
| LTM Aug 2026 | $19.76M | -5.9% | -10.9% | 2.2% | |
| Peer median (excluding IDXX) | $551.5M | +6.4% | +1.0% | 7.5% | |
Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.22B | 3.37B | 3.66B | 3.9B | 4.3B |
| Cost of Revenue | 1.33B | 1.36B | 1.47B | 1.52B | 1.64B |
| Gross Profit | 1.89B | 2B | 2.19B | 2.38B | 2.66B |
| Gross Margin | 58.8% | 59.5% | 59.8% | 61.0% | 61.8% |
| Research & Development | 161.01M | 254.82M | 190.95M | 219.79M | 251.21M |
| Selling, General & Admin | 796.4M | 850.75M | 901.89M | 1.03B | 1.05B |
| Operating Expenses | 957.4M | 1.11B | 1.09B | 1.25B | 1.3B |
| Depreciation & Amortization | 104.6M | 111.9M | 114.91M | 129.94M | 145.18M |
| EBITDA | 1.04B | 1.01B | 1.22B | 1.28B | 1.51B |
| EBITDA Margin | 32.3% | 30.1% | 33.3% | 32.7% | 35.0% |
| Operating Income | 932.03M | 898.77M | 1.1B | 1.13B | 1.36B |
| Operating Margin | 29.0% | 26.7% | 30.0% | 29.0% | 31.6% |
| Interest Income | 434K | 1.07M | 5.63M | 12.7M | 2.42M |
| Interest Expense | 29.81M | 39.86M | 41.58M | 31.21M | 38.27M |
| Other Income / Expenses | (29.37M) | (38.79M) | (35.95M) | (18.51M) | (35.84M) |
| Income Before Tax | 902.65M | 859.97M | 1.06B | 1.11B | 1.32B |
| Pre-Tax Margin | 28.1% | 25.5% | 29.0% | 28.5% | 30.8% |
| Income Tax Expense | 157.81M | 180.88M | 216.13M | 221.96M | 264.73M |
| Net Income | 744.85M | 679.09M | 845.04M | 887.87M | 1.06B |
| Net Margin | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% |
| EPS (Basic) | 8.74 | 8.12 | 10.17 | 10.77 | 13.17 |
| EPS (Diluted) | 8.60 | 8.03 | 10.06 | 10.67 | 13.08 |
| Weighted Avg Shares | 85.2M | 83.62M | 83.07M | 82.47M | 80.1M |
| Weighted Avg Shares (Diluted) | 86.57M | 84.6M | 83.98M | 83.25M | 80.68M |
IDEXX Laboratories, Inc.
NASDAQ:IDXX
Intrinsic Alpha fair value
Locked
Current Price
$698.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.